January 8, 2024 - HighField Bio

January 8, 2024 in Press Release

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors HANGZHOU, China--January 8, 2024--HighField Biopharm ...

HighField Biopharmaceuticals Company Profile – 2024

HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys

HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors